Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non-small cell lung cancer patients at a lung cancer center in China.

Journal: Thoracic cancer

Published Date: Mar 19, 2020

Abstract

BACKGROUND: IBM Watson for Oncology (WFO) provides physicians with evidence-based treatment options. This study was designed to explore the concordance of the suggested therapeutic regimen for advanced non-small cell lung (NSCLC) cancer patients between the updated version of WFO and physicians in our department, in order to reflect the differences of cancer treatment between China and the United States.

Authors

Shuyang Yao

Department of thoracic surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Ruotian Wang

Department of thoracic surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Kun Qian

Key Laboratory of Brain Health Intelligent Evaluation and Intervention (Beijing Institute of Technology), Ministry of Education, Beijing, China.
Yi Zhang

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.

Keywords

Adenocarcinoma of Lung Artificial Intelligence Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell China Clinical Decision-Making Decision Support Systems, Clinical Evidence-Based Medicine Female Follow-Up Studies Humans Lung Neoplasms Male Middle Aged Patient Selection Practice Guidelines as Topic Prognosis Retrospective Studies Survival Rate United States

External Resources

View on PubMed Access via DOI PubMed (32191394)

Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non-small cell lung cancer patients at a lung cancer center in China.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals